Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Lazertinib plus Pemetrexed/Carboplatin in EGFR-mutant Metastatic NSCLC with Brain Metastases After Osimertinib Failure
KCT0007109Phase 2Completed
- Sponsor
- Korean Cancer Study Group
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lazertinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Korean Cancer Study Group. Started Aug 2022; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on KCT0007109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007109.